PolyPeptide Group AG shareholders approved all proposals from the Board of Directors at the company's fifth annual General Meeting with a large majority. The meeting, held at the Chollerhalle in Zug, Switzerland, saw 80.85% of issued registered shares represented, totaling 26,780,855 shares with voting rights.
All six members of the Board of Directors proposed for re-election were appointed for terms ending at the conclusion of the next annual General Meeting in 2027. Peter Wilden was re-elected as Chair of the Board of Directors, while Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for the same term.
Additional approved proposals included the re-election of Statutory Auditors and the Independent Proxy, along with approval of maximum aggregate compensation amounts for the Board of Directors and Executive Committee. Shareholders granted discharge to all members of the Board of Directors and Executive Committee for their activities during the 2025 financial year.
The Management Report, Statutory Financial Statements, Consolidated Financial Statements, and report on non-financial matters for 2025 were approved, as was the Remuneration Report 2025 in a separate consultative vote. The minutes of the AGM 2026 will be available within 15 days on the company's website at https://polypeptide.com.
This shareholder approval demonstrates continued confidence in PolyPeptide's leadership during a period of significant growth in the peptide therapeutics market. As a specialized Contract Development & Manufacturing Organization for peptide-based active pharmaceutical ingredients, PolyPeptide serves pharmaceutical and biotechnology companies, contributing to treatments for millions of patients worldwide with particular exposure to metabolic diseases including GLP-1 therapies.
The company's global network includes six GMP-certified facilities across Europe, the United States, and India, positioning it to capitalize on increasing demand for peptide-based treatments. The strong shareholder support suggests investors believe current management is effectively navigating market opportunities while maintaining corporate governance standards.
The next annual General Meeting is scheduled for April 7, 2027, providing the next formal opportunity for shareholder engagement with company leadership. The comprehensive approval of all board proposals indicates alignment between management and investors regarding the company's strategic direction and operational oversight.
